BTG Share Price (BTG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
BTG Plc	LSE:BTG	London	Ordinary Share	GB0001001592	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+1.50p	+0.27%	564.50p	1,100,352	16:35:15

Bid Price		Offer Price	High Price	Low Price	Open Price
566.00p		566.50p	577.50p	562.00p	563.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Support Services	620.50	-70.60	3.90	144.7	2,186.4

Related Shares
Experian (EXPN), Ferguson (FERG), Kellan Group (KLN), Nakama (NAK)

BTG (BTG) Latest News

BTG News

Date	Time	Source	Headline
20/9/2018	07:00	PRNUS	BTG Announces Global Launch of the ICEfx™ Cryoablation System
20/9/2018	07:00	PRNUS	BTG Announces Global Launch of the ICEfx™ Cryoablation System
13/9/2018	13:00	PRNUS	FDA Approves CroFab® Product Improvements
07/9/2018	16:10	BW	BTG plc acquires Novate Medical Ltd.
07/9/2018	07:53	ALNC	BTG Buys Medical Device Outfit Novate Medical For Up To USD20 Million
07/9/2018	07:02	ALNCF	Alliance News Flash Headline
07/9/2018	07:00	UKREG	BTG PLC BTG plc acquires Novate Medical Ltd
03/9/2018	10:20	UKREG	BTG PLC Total Voting Rights
09/8/2018	08:47	ALNC	BTG Receives FDA Rejection Confirmation For Elevair Coil System
09/8/2018	07:01	UKREG	BTG PLC Regulatory Update

More BTG News

BTG Takeover Rumours

BTG (BTG) Share Charts

1 Year BTG Chart

1 Month BTG Chart

Intraday BTG Chart

BTG (BTG) Discussions and Chat

BTG Forums and Chat

Date	Time	Title	Posts
23/9/2018	08:46	BTG	5,748
12/11/2013	08:46	BTG down the tube	6
09/3/2012	07:16	Bright Things	3
10/9/2004	20:24	Varisolve hits the FDA buffer's	6

Add a New Thread

BTG (BTG) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all BTG trades in real-time

BTG (BTG) Top Chat Posts

Date	Subject
23/9/2018 09:20	BTG Daily Update: BTG Plc is listed in the Support Services sector of the London Stock Exchange with ticker BTG. The last closing price for BTG was 563p. BTG Plc has a 4 week average price of 535.50p and a 12 week average price of 467.40p. The 1 year high share price is 784p while the 1 year low share price is currently 467.40p. There are currently 387,314,436 shares in issue and the average daily traded volume is 670,468 shares. The market capitalisation of BTG Plc is £2,186,389,991.22. Read Full Thread Reply
18/8/2018 17:42	spyder: Curiously, the explanation given in today’s Times for the share price rise is “shift towards a product sales business pleases investors.” I’m not sure why that happened at 1pm yesterday?! Read Full Thread Follow Reply
25/7/2018 08:18	spyder: This is a welcome respite although I wouldn’t get too excited at this stage as, given the time of the year, it seems to me very unlikely that anyone would launch a bid at the beginning of August. As also noted above, clearly he Board had no clue given the recent shares purchase. This could just be a ‘silly season’ Pump and Dump rumour OR I suppose there could be something in it? Looking at the share price action yesterday, it seems clear that the story came out of the US (home of the Pump and Dump!) but, but, but, if there is ever a bidder, they are much more likely to come from the US than anywhere else, and as pointed out above, they will strike when the £/$ exchange rate is low, and when the UK market undervalues the company’s prospects, which it is presently doing - massively. I suspect there are a few companies out there watching... possibly even including J&J?? If they were optimistic about a long term revenue stream from Zytiga, they could buy BTG, close out the royalty stream and sell on the rest - simple but effective arbitrage ... Read Full Thread Follow Reply
25/7/2018 07:42	bargainbob: One of Britain’s most prominent healthcare companies shot to the top of the FTSE 250 amid speculation that it was being considered a takeover target. BTG closed up 6.7 per cent, or 33¼p, at 529½p as rumours spread of preparations for a bid. The company’s share price has tumbled by 30 per cent since the start of the year, a fall that accelerated amid reports of a £102.8 million operating loss for the year to the end of March. BTG took a £144.7 million charge after delays with Pneumrx, its emphysema treatment, which subsequently failed to win backing from a key panel of the US Food and Drug Administration. Read Full Thread Follow Reply
11/7/2018 07:42	bargainbob: The best shareholders could hope for is a takeover. Glassdoor reviews do not paint management in a better light than the above unfortunately. As a long term BTG holder , so sad to see good windfalls wasted and diverted to mangers via bonus payments . I do not know how Louise can survive this , though I fear if she went it would be another blow to the share price. I also believe any takeover would be at around the current price. Read Full Thread Follow Reply
30/6/2018 17:12	bargainbob: Surprised the Amazon deal did not lift the BTG share price. Read Full Thread Follow Reply
15/6/2018 06:30	spyder: Re the Wellstat appeal loss in Delaware, I am a little surprised that BTG haven't released the news to the market given it happened on Monday. I guess it depends on whether this is a regulatory newsworthy event, and that in turn depends on whether the news will move the share price. Again, maybe the outcome has been anticipated, and the fine already provided for, I guess we'll see what happens to the shares, but it could be argued that there has been a false market for the last 4 days with the shares drifting lower. I suppose now it will be difficult to untangle the outcome from the FDA news overnight. Read Full Thread Follow Reply
16/6/2017 11:54	aphrodites: Having suffered a DVT myself a couple of years ago in my right leg and with a vein from my knee to my groin now blocked for life, I am probably more aware than most about the advantages the treatment with the EKOS system will provide to the medical world. The present treatment to unblock veins is very primitive and the success rate very, very low indeed. The damage caused to the valves in veins is irreparable unless the blockage is cleared very quickly. The market for the treatment of DVTs is massive and contrary to general opinion the condition is not restricted just to the elderly. I am reliably informed by an air hostess that a young lady of 34 y.o.a suffered a DVT on a flight and actually died on the plane. DVT's are very common indeed. I did have the statistics somewhere but cannot put my hands on them. Maybe someone else can provide. The announcement today has in my opinion far greater implications to the BTG share price than is fully appreciated and I am surprised the price is not back over £7 and moving higher. But it is a Friday. Obviously we will have to wait for the analysts to digest the news and get the blue pencils out next week. Have a good weekend everyone. Onwards and upwards. Read Full Thread Follow Reply
13/6/2017 20:01	aphrodites: fhmktg You should breath in again and wait for news possibly on the 15th which could be very important for the share price. And as for Crofab why not update everyone with the news released today, not massive but nevertheless interesting and was not the reason for today's price rise??????????? New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation PHILADELPHIA, June 13, 2017 /PRNewswire/ -- A study sponsored by BTG plc (LSE: BTG), the global specialist healthcare company, has been recently published in the Annals of Emergency Medicine (AEM) that shows administering CroFab® to patients envenomated by copperhead snakes can aid the recovery of a patient's affected limb function as compared with placebo. (Logo: hxxp://photos.prnewswire.com/prnh/20150805/255981LOGO ) The randomised, double-blind, placebo-controlled study compared CroFab® Crotalidae Polyvalent Immune Fab (Ovine) - the only antivenom currently marketed for the treatment of crotaline snake envenomation - against placebo for the treatment of copperhead snake envenomation for the first time. Copperhead envenomation is generally considered less severe than other North American Pit Viper snakebites, but more than 95% of copperhead victims still develop significant pain and swelling of the injured limb, and other soft tissue injury. Most patients resume activities within 2-4 weeks but residual symptoms can last for a year. Dr Charles Gerardo, Chief of Emergency Medicine at Duke University and expert in Copperhead snake envenomation, said: "For the first time, this data demonstrates that CroFab® improves recovery of limb function from Copperhead envenomation. Additionally, antivenom treatment was associated with less opioids use throughout the patient's recovery. These results can be used to help physicians and patients make a more informed choice about their care." In total, 74 patients participated in the study; 45 were treated with CroFab® and the rest received a placebo. All participating trial staff (apart from the study pharmacist) and patients were unaware of the treatment given in each case. Within the patient cohort was a mix of upper and lower extremity conditions depending on where the copperhead had bitten the patient. The Patient Specific Functional Scale (PSFS) was used to measure study outcomes by assessing each patient's ability to do daily activities that they were unable to do or had difficulty with post copperhead inflicted injury. The tasks varied from driving a car, climbing the stairs, brushing teeth, or using a cell phone and took in to account the score at envenomation + 14 days using a 0-10 scale. In addition to the positive primary outcome of the study, it was also discovered that opioid analgesic use was less in CroFab® treated patients. Dan Schneider, SVP and General Manager, Specialty Pharmaceuticals, Commercial Operations at BTG, said: "We are pleased with the clinical study findings that show that patients treated with CroFab® recover faster from Copperhead bites. Even though we haven't reached summer months yet, we are seeing multiple reports stating that the frequency of bites in the U.S. are on the rise this year. As snake sightings start to pick up, don't forget to download our free, educational SnakeBite911™ App Suite. It has useful information about the dos and don'ts if envenomation occurs and helps raise awareness about North American Pit Vipers." To review the published article in full, please refer to the following link: hxxp://www.annemergmed.com/article/S0196-0644(17)30510-3/fulltext. Indication CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins. Important Safety Information The most common adverse reactions reported in the clinical studies were urticaria, rash and nausea. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Anaphylaxis and hypersensitivity reactions can occur, and patients should be monitored closely during treatment. CroFab® should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required rehospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug. About BTG BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com. For further information contact: BTG Andy Burrows, VP Corporate & Investor Relations Read Full Thread Follow Reply
13/10/2015 11:54	cyman: well the last sell recommendation to 565 (I think it was) proved to be a huge success and we were all laughing at it when we were basking in the sunshine of 800p. btg share price reactions of the past have often proven themselves to have been huge over-reactions - like when Louise settled her divorce, everyone was accusing her of all manner of sorcery - so hopefully this too was nothing more than an over reaction and we can start to settle back into the 600's whilst we await next years forecasts etc. Read Full Thread Follow Reply
21/6/2015 12:08	spyder: Here are my thoughts on what is happening with the BTG share price, for what they are worth. I suggested in posts to this board several times in the last few months, and most recently at around the time of the results, that the BTG share price was approaching very dangerous chart territory. If it failed to rally, then there would be no support for the shares going forward. Unfortunately, I didn’t “put my money where my mouth was”, because subsequent events proved my comments to be correct and the shares have dropped approximately 20% in the last month or so. I’m afraid the news doesn’t get any better, as, again looking at the chart, this share only has one way to go, and it will continue falling. There could be support at £6.00, and again at £5.00, but I won’t be around to see £5.00 tested if that were to happen and I have an opportunity to exit. To those of you who think charts are nonsense and it is all about the fundamentals, I say that the charts have called it absolutely right so far, in spite of broadly unchanged fundamentals. Indeed, looking at BTGs own forecasts, and almost universally those of the analysts, the outlook remains a positive as ever, so why the freefall? And where are the value buyers? The next few weeks will be a classic test of predicting share price by chart vs fundamentals. If the chart wins, we are heading lower, perhaps significantly. If the fundamentals are to be believed, then value investors should pile in before long. My own strategy is to continue holding, because my investment timeframe is 5 to 10 years, so perhaps one day this will be seen as just another pothole on the road to the FTSE 100. HOWEVER, if the shares fall to £5.80 and linger for more than a day or so, I’m out. Unfortunately I have seen too many extremely successful shares tank for no reason given the fundamentals, only to see that the fundamentals turned out to be hot air. The market (and the chart) usually (but not always!) knows best. Read Full Thread Follow Reply

BTG share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:31 V: D:20180924 05:13:30